Financial Performance
Operating Performance
Explanation of any material differences compared to the previous year’s results or any forecasts announced by the Company.
Performance at a glance
Operating Results
Net Revenue
460.485
million16.9%change from 2024
Operating Profit
110.213
million21.1%change from 2024
Net Profit for the Year
97.009
million21.5%change from 2024
Complete operating results
Operating Results
Explanation of any material differences compared to the previous year’s results or any forecasts announced by the Company.
Scroll horizontally to review every column.
| Item | 2025 | % | 2024 | % | Change Between 2024 – 2025 | % Change 2024 – 2025 |
|---|---|---|---|---|---|---|
| Net Revenue | 460.485 | 100.0% | 394.001 | 100.0% | 66.484 | 16.9% |
| Cost of Sales | (173.647) | -37.7% | 150.638 | -38% | 23.009 | 15.3% |
| Gross Profit | 286.838 | 62.3% | 243.362 | 61.8% | 43.476 | 17.9% |
| Selling and Distribution Expenses | (116.116) | -25.2% | 96.190 | -24.4% | 19.926 | 20.7% |
| General and Administrative Expenses | (59.079) | -12.8% | 53.757 | -13.6% | 5.322 | 9.9% |
| Total Selling and Administrative Expenses | (175.195) | -38.0% | 149.947 | -38.1% | 25.248 | 16.8% |
| Provision/Loss for Bad Debts | (1.466) | -0.3% | 3.537 | -0.9% | -2.071 | -58.6% |
| Other Income/Expenses | 0.035 | 0.0% | 1.155 | 0.3% | -1.120 | -97.0% |
| Operating Profit | 110.213 | 23.9% | 91.034 | 23.1% | 19.179 | 21.1% |
| Finance Costs | (6.473) | -1.4% | 4.685 | -1.2% | 1.788 | 38.2% |
| Profit Before Zakat | 103.740 | 22.5% | 86.349 | 21.9% | 17.391 | 20.1% |
| Zakat Expense | (6.730) | -1.5% | 6.500 | -1.6% | 0.230 | 3.5% |
| Net Profit for the Year | 97.009 | 21.1% | 79.849 | 20.3% | 17.160 | 21.5% |
| Net Profit Margin | 21.1% | 20.3% |
Activity mix
Description of the Principal Types of Activities of the Company and Its Subsidiaries
Where two or more types of activity are described, a statement for each activity shall be included, setting out its impact on the Company’s business volume and its contribution to the results.
Principal Activities of the Company:
Avalon Pharma operates in the development, manufacturing, and marketing of generic medicines and pharmaceutical products, including prescription and other medications. The Company’s principal activities are as follows:
- Pharmaceutical Products
- Over-the-Counter (OTC) Products
These activities contributed to the Company’s business and results as follows:
- Pharmaceutical Products57%
261,354.5thousand
- Over-the-Counter (OTC) Products43%
199,130.3thousand
Scroll horizontally to review every column.
| Principal Activity of the Company | Activity Revenue (ر Thousands) | Percentage % |
|---|---|---|
| Pharmaceutical Products | 261,354.5 | 57% |
| Over-the-Counter (OTC) Products | 199,130.3 | 43% |
| Total | 460,484.8 | 100% |
Principal Activities of the Subsidiaries:
Scroll horizontally to review every column.
| Subsidiary | Activity | Activity Revenue (ر Thousands) | Percentage % |
|---|---|---|---|
| Avalon Pharma UK Holdings Limited | Manufacturing of pharmaceuticals, medicated and non-medicated creams, and ointments. | 0.00 | 00% |
Accounting context
Compliance with the standards approved by the Saudi Organization for Certified Public Accountants (SOCPA).
Clarification of any cases of non-compliance with the standards adopted by the Saudi Organization for Certified Public Accountants and professionals.
There are no conflicts with the standards adopted by the Saudi Organization for Certified Public Accountants and professionals, and our consolidated financial statements have been prepared in accordance with the International Financial Reporting Standards (IFRS) adopted in the Kingdom of Saudi Arabia, as well as other standards and issuances issued by the Saudi Organization for Certified Public Accountants and professionals.